{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:42:19Z","timestamp":1790660539284,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.critrevonc.2015.05.008","type":"journal-article","created":{"date-parts":[[2015,5,27]],"date-time":"2015-05-27T08:32:16Z","timestamp":1432715536000},"page":"100-112","source":"Crossref","is-referenced-by-count":103,"title":["Papillary renal cell carcinoma: A review of the current therapeutic landscape"],"prefix":"10.1016","volume":"96","author":[{"given":"Giulia","family":"Courthod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.critrevonc.2015.05.008_bib0605","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"NETM"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0610","first-page":"1001","article-title":"Family history and risk of renal cell carcinoma","volume":"10","author":"Gago-Dominiguez","year":"2011","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0615","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6161","key":"10.1016\/j.critrevonc.2015.05.008_bib0620","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","article-title":"Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma","volume":"332","author":"Seizinger","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0625","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","article-title":"Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer","volume":"66","author":"Banks","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0630","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0635","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0640","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrclinonc.2010.42","article-title":"Alterations in VHL as potential biomarkers in renal-cell carcinoma","volume":"7","author":"Gossage","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.05.008_bib0645","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"09 (May 1)","key":"10.1016\/j.critrevonc.2015.05.008_bib0650","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","article-title":"Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0655","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1002\/cncr.22340","article-title":"Treatment outcome for metastatic papillary renal cell carcinoma patients","volume":"107","author":"Ronnen","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0660","unstructured":"WHO Classification of Tumors. Third edition."},{"issue":"6 (Jun)","key":"10.1016\/j.critrevonc.2015.05.008_bib0665","first-page":"537","article-title":"Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors","volume":"10","author":"Delahunt","year":"1997","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.05.008_bib0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2006.09.052","article-title":"Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of Type 1 and Type 2 subclassification","volume":"69","author":"Pignot","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0675","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1158\/1078-0432.CCR-08-1229","article-title":"Cytogenetic and molecular tumor profiling for Type 1 and Type 2 papillary renal cell carcinoma","volume":"15","author":"Klatte","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0680","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0022-5347(17)35015-2","article-title":"Hereditary papillary renal cell carcinoma","volume":"151","author":"Zbar","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0685","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.lungcan.2008.06.011","article-title":"MET as a target for treatment of chest tumors","volume":"63","author":"Cipriani","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0690","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2013.02.001","article-title":"The emerging role of MET\/HGF inhibitors in oncology","volume":"39","author":"Scagliotti","year":"2013","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0695","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0700","first-page":"1719","article-title":"Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene","volume":"58","author":"Schmidt","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0705","doi-asserted-by":"crossref","unstructured":"Bernues M, Casadevall C, Miro R, Caballin MR, Villavicencio H, Salvador J, et al. Cytogenetic characterization of a familial papillary renal cell carcinoma. Cancer Genet Cytogenet 84, 123\u2013127.","DOI":"10.1016\/0165-4608(95)00044-5"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0710","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000134448","article-title":"Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridixation","volume":"75","author":"Bentz","year":"1996","journal-title":"Cytogenet Cell Genet"},{"issue":"4 (Apr)","key":"10.1016\/j.critrevonc.2015.05.008_bib0715","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/jmg.2010.085068","article-title":"Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma","volume":"48","author":"Gardie","year":"2011","journal-title":"J Med Genet"},{"issue":"1 (Jan)","key":"10.1016\/j.critrevonc.2015.05.008_bib0720","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/PAS.0b013e31825ec16f","article-title":"Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome","volume":"37","author":"Sanz-Ortega","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0725","doi-asserted-by":"crossref","unstructured":"Sudarshan S, Shanmugasundaram K, Naylor SL, Lin S, Livi CR, O\u2019Neill CF, et al. Reduced Expression of fumarate Hydratase in Clear Cell Renal Cancer Mediates HIF-2a Accumulation and Promotes Migration and Invasion. PLoS ONE 6(6): e21037.","DOI":"10.1371\/journal.pone.0021037"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0730","doi-asserted-by":"crossref","DOI":"10.1007\/s004390000348","article-title":"Molecular genetic advances in tuberous sclerosis","volume":"107","author":"Cheadle","year":"2000","journal-title":"Hum Genet"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0735","series-title":"Cancer Syndromes.","article-title":"Birt-Hogg-Dub\u00e9 syndrome","author":"Reese","year":"2009"},{"issue":"14 (Apr 8)","key":"10.1016\/j.critrevonc.2015.05.008_bib0740","first-page":"2343","article-title":"Novel mutations of the MET proto-oncogene in papillary renal carcinomas","volume":"18","author":"Schmidt","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0745","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)65147-4","article-title":"Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype","volume":"155","author":"Lubensky","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0750","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-5347(05)64830-6","article-title":"Biological significance of c-met over expression in papillary renal cell carcinoma","volume":"168","author":"Sweeney","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0755","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3346\/jkms.2006.21.4.672","article-title":"Met expression in sporadic renal cell carcinomas","volume":"21","author":"Choi","year":"2006","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0760","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s004280050282","article-title":"Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth","volume":"433","author":"Inoue","year":"1998","journal-title":"Virchows Arch"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0165","article-title":"Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information","author":"Yu","year":"2012","journal-title":"Acta Histochemica"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0765","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0002-9440(10)65734-3","article-title":"Chromosomal imbalances in papillary renal cell carcinoma. Generic differences between histological subtypes","volume":"153","author":"Jiang","year":"1998","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0770","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0002-9440(10)64260-5","article-title":"Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma","volume":"161","author":"Sanders","year":"2002","journal-title":"American Journal of Pathology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0775","first-page":"1544","article-title":"Histopathological, cytogenetic, and molecular characterization of renal cortical tumors","volume":"51","author":"Presti","year":"1991","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0780","first-page":"5780","article-title":"Allelic deletions in renal tumors: Histopathological correlations","volume":"53","author":"Presti","year":"1993","journal-title":"Cancer Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0785","first-page":"6200","article-title":"Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: Evidence for a cytogenetic evolution of type 2 from type 1 tumors","volume":"63","author":"Gunawan","year":"2003","journal-title":"Cancer Research"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.05.008_bib0790","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/gcc.2870030403","article-title":"Cytogenetics of papillary renal cell tumors","volume":"3","author":"Kovacs","year":"1991","journal-title":"Genes, Chromosomes and Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0795","first-page":"27","article-title":"Papillary renal cell carcinoma. A morphologic and cytogenetic study of 11 cases","volume":"134","author":"Kovacs","year":"1989","journal-title":"American Journal of Pathology"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.05.008_bib0800","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00019606-199603000-00009","article-title":"Papillary renal cell carcinoma: quantitation of chromosomes 7 and 17 by FISH, analysis of chromosome 3p for LOH, and DNA ploidy","volume":"5","author":"Corless","year":"1996","journal-title":"Diagnostic Molecular Pathology"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.05.008_bib0805","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/1097-0142(19950815)76:4<669::AID-CNCR2820760420>3.0.CO;2-U","article-title":"Papillary renal tumors, Morphologic, cytochemical, and genotypic features","volume":"76","author":"Lager","year":"1995","journal-title":"Cancer 15"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0810","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1073\/pnas.92.7.2854","volume":"92","author":"Thrasch-Bingham","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0815","first-page":"6189","article-title":"Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology","volume":"55","author":"Thrasch-Bingham","year":"1995","journal-title":"Cancer research"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.05.008_bib0820","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(93)90050-V","article-title":"Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype","volume":"65","author":"Meloni","year":"1993","journal-title":"Cancer Genetics and Cytogenetics"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.05.008_bib0825","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000134127","article-title":"Mapping the X chromosome breakpoint in two papillary renal cell carcinoma cell lines with a t(X;1)(p11.2;q21.2) and the first report of a female case","volume":"71","author":"Shipley","year":"1995","journal-title":"Cytogenetics and Cell Genetics"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0830","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0165-4608(98)00181-2","article-title":"Two new cases of papillary renal cell carcinoma with t(X;1)(p11;q21) in females","volume":"110","author":"Perot","year":"1999","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0835","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/hmg\/5.9.1333","article-title":"The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene","volume":"5","author":"Swidhar","year":"1996","journal-title":"Human Molecular Genetics"},{"issue":"10 (Oct)","key":"10.1016\/j.critrevonc.2015.05.008_bib0840","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"ISUP renal tumor panel. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0845","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.med.59.053006.104707","article-title":"MicroRNAs in cancer","volume":"60","author":"Garzon","year":"2009","journal-title":"Annual Review of Medicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.05.008_bib0850","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3892\/ijo_00000318","article-title":"MicroRNA profiling of human kidney cancer subtypes","volume":"35","author":"Petillo","year":"2009","journal-title":"International Journal of Oncology"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.05.008_bib0855","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/bjc.2013.313","article-title":"MicroRNA profiles classify papillary renal cell carcinoma subtypes","volume":"109","author":"Wach","year":"2013","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0860","doi-asserted-by":"crossref","first-page":"41.e1","DOI":"10.1016\/j.urolonc.2013.04.011","article-title":"Urine microRNAs as a potential noninvasive biomarkers in urologic cancers","volume":"32","author":"Mlcochova","year":"2014","journal-title":"Urologic Oncology: Seminar and Original Investigations"},{"issue":"22","key":"10.1016\/j.critrevonc.2015.05.008_bib0865","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, IFN-a or Both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.05.008_bib0870","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of Temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Medical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0875","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of Sunitinib for metastatic renal-cell carcinoma: An expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0880","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2002.11.123","article-title":"Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology","volume":"20","author":"Motzer","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0885","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","article-title":"Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma","volume":"26","author":"Choueiri","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0890","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdr586","article-title":"Multicenter phase II study of Sunitinib in patients with non-clear cell renal cell carcinoma","volume":"23","author":"Lee","year":"2012","journal-title":"Annals of Oncology"},{"issue":"Suppl 4","key":"10.1016\/j.critrevonc.2015.05.008_bib0895","article-title":"Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology","volume":"32","author":"Escudier","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.05.008_bib0900","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10637-010-9491-6","article-title":"Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma","volume":"30","author":"Molina","year":"2012","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.05.008_bib0905","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A phase 2 trial of sunitinib in patients with advanced non- clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"European Urology"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.05.008_bib0910","first-page":"110","article-title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America","volume":"7","author":"Stadler","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0915","doi-asserted-by":"crossref","DOI":"10.1016\/S0923-7534(20)33364-0","article-title":"First line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP-a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase Trials (GEP)","author":"Ravaud","year":"2012","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0920","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/annonc\/mdt578","article-title":"Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies","volume":"25","author":"Voss","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0925","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.4505","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal carcinoma (the ESPN Trial): A randomized multicenter phase 2 trial","volume":"32","author":"Tannir","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0930","unstructured":"NCT01185366 Everolimus versus sunitinib in non-clear cell renal cell carcinoma. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0935","unstructured":"NCT01108445 Phase II of Afinitor vc. Sutent in patients with metastatic non-clear cell renal cell carcinoma. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0940","unstructured":"NCT01538238 Pazopanib_NCRCC, Ph 2 STUDY. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0945","unstructured":"NCT01767636 Pazopanib in treating patients with metastatic non-clear cell kidney cancer. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0950","unstructured":"NCT00465179 Sunitinib malate in patients with non-clear cell renal cell cancer. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0955","unstructured":"NCT01399918 Everolimus and Bevacizumab in advanced non-clear cell renal cell carcinoma (RCC). ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0960","unstructured":"NCT01206764 A Trial of everolimus in patients with advanced renal cell carcinoma. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0965","unstructured":"NCT01888042 Assessing everolimus in first line treatment on patients with metastatic kidney cancer. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0970","unstructured":"NCT01517243 Phase II of alterning sunitinib and temsirolimus. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0975","unstructured":"NCT01798446 A phase II study of axitinib in metastatic non-clear cell renal cell carcinoma previously treated with temsirolimus. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0980","unstructured":"NCT01164228 Sunitinib malate with or without gemcitabine hydrochloride in treating patients with advanced kidney cancer that cannot be removed by surgery. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0985","unstructured":"NCT02187302 CRLX101 in Combination with bevacizumab for metastatic renal cell carcinoma (mRCC) versus standard of care (SOC). ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0990","unstructured":"NCT01664182 Trebananib with or without bevacizumab, pazopanib hydrochloride, sorafenib tosylate, or sunitinib malate in treating patients with advanced kidney cancer. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib0995","unstructured":"NCT01122615 Sunitinib plus temsirolimus in patients with renal cell cancer (RCC). ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1000","unstructured":"NCT00459875 Sunitinib in treating patients with locally recurrent or metastatic kidney cancer. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1005","unstructured":"NCT00459979 Sunitinib in treating patients with kidney cancer that cannot be removed by surgery. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1758834011408636","article-title":"The role of c-MET pathway in lung cancer and the potential for targeted therapy","volume":"3","author":"Sattler","year":"2011","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1015","doi-asserted-by":"crossref","unstructured":"Van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM. Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms. Drug Resistance Updates 17 82014; 77\u201388.","DOI":"10.1016\/j.drup.2014.10.003"},{"issue":"20 (Oct 15)","key":"10.1016\/j.critrevonc.2015.05.008_bib1020","first-page":"28009","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res"},{"issue":"4 (Aug)","key":"10.1016\/j.critrevonc.2015.05.008_bib1025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s10637-011-9699-0","article-title":"Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks","volume":"30","author":"Kataoka","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1030","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-10-0574","article-title":"A phase I study of Foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial Growth factor receptor 2","volume":"16","author":"Eder","year":"2010","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the Dual MET\/VEGFR2 inhibitor Foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1040","unstructured":"\u3008http:\/\/www.exelixis.com\/pipeline\/xl880\u3009."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1045","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1002\/cncr.27582","article-title":"Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial","volume":"1","author":"Wagner","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1050","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1200\/JCO.2010.32.6223","article-title":"Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer","volume":"29","author":"Haq","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1055","unstructured":"NCT01688973 Tivantinib with or without erlotinib hydrochloride in treating patients with metastatic or locally advanced kidney cancer that cannot be removed by surgery. ClinicalTrials.gov."},{"issue":"22","key":"10.1016\/j.critrevonc.2015.05.008_bib1060","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A novel kinase inhibitor, INCB28060, Blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1065","unstructured":"NCT01737827 study efficacy and safety of INC280 in patients with advanced hepatocellular carcinoma. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1070","unstructured":"NCT02019693 A phase II study of the MET kinase inhibitor INC280 in papillary renal cell cancer. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1075","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1535-7163.TARG-11-A233","article-title":"Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone","volume":"10","author":"Schimmoller","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1080","doi-asserted-by":"crossref","unstructured":"Basch E, Scholz MC, De Bono JS, Vogelzang NJ, De Souza PL, Marx GM, et al. Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone\/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRCP) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A9 and\/or enzalutamide 8E). J clin Oncol 22, 2015 (suppl 7, abs 141).","DOI":"10.1200\/jco.2015.33.7_suppl.141"},{"issue":"8 (Aug)","key":"10.1016\/j.critrevonc.2015.05.008_bib1085","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","article-title":"A phase I study of cabozantinib (XL184) in patients with renal cell cancer","volume":"25","author":"Choueiri","year":"2014","journal-title":"Annals of Oncology"},{"issue":"25 (Jun 20)","key":"10.1016\/j.critrevonc.2015.05.008_bib1090","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1095","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1158\/1541-7786.MCR-08-0522","article-title":"Exon array profiling detects EML4-ALK fusion in breast, colorectal and non-small cell lung cancers","volume":"7","author":"Lin","year":"2009","journal-title":"Molecular Cancer Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1100","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/modpathol.2012.107","article-title":"ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients","volume":"25","author":"Sukov","year":"2012","journal-title":"Modern Pathology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1105","unstructured":"NCT01524926 CREATE: Cross-tumoral Phase 2 with Crizotinib. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1110","doi-asserted-by":"crossref","unstructured":"R. Schoffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, et al. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Intern 108, 679\u2013686.","DOI":"10.1111\/j.1464-410X.2010.09947.x"},{"issue":"5","key":"10.1016\/j.critrevonc.2015.05.008_bib1115","article-title":"First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504\/AZD6094) in patients with advanced solid tumors","volume":"32","author":"Gan","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1120","unstructured":"NCT02127710 A phase II trial to evaluate the efficacy of AZD6094 (HMPL-504) in patients with papillary renal cell carcinoma (PRCC). ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1125","first-page":"913","article-title":"Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis","volume":"1","author":"Uhlman","year":"1995","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1096-9896(199804)184:4<424::AID-PATH1223>3.0.CO;2-A","article-title":"EGF-r Gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization","volume":"184","author":"Moch","year":"1998","journal-title":"Journal of Pathology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1135","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/cncr.26436","article-title":"Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma","volume":"1","author":"Minner","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1140","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2008.18.8821","article-title":"Phase II study of Erlotinib in patients with locally advanced or metastaticpapillary histology renal cell cancer: SWOG s0317","volume":"27","author":"Gordon","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1145","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1757","key":"10.1016\/j.critrevonc.2015.05.008_bib1150","first-page":"1761","article-title":"EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients","volume":"22","author":"Sakeda","year":"2005","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1155","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (Anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11864-013-0268-y","article-title":"Potential of new therapies like anti-PD1 in kidney cancer","volume":"15","author":"Gunturi","year":"2014","journal-title":"Current Treatment Options in Oncology"},{"issue":"11 (Nov)","key":"10.1016\/j.critrevonc.2015.05.008_bib1165","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 expression in nonclear-cell renal cell carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1170","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancers","volume":"366","author":"Topalian","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1175","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1180","unstructured":"NCT01354431 BMS-936558 (MDX-1106) In subjects with advanced\/metastatic clear-cell renal cell carcinoma (RCC). ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1185","unstructured":"NCT01472081 Nivolumumab (BMS-936558; MDX-1106) in combination with sunitinib, pazopanib, or ipilimumab in subjects with metastatic renal cell carcinoma (RCC). ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1190","unstructured":"NCT02231749 Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma. ClinicalTrials.gov."},{"key":"10.1016\/j.critrevonc.2015.05.008_bib1195","unstructured":"NCT01668784 Study of Nivolumab (BMS-936558) vs. Everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma. ClinicalTrials.gov."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815000979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T06:45:52Z","timestamp":1717915552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815000979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1040842815000979"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.05.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}